Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway

Christine Årdal; Jostein Johnsen; Karianne Johansen

doi:10.1177/1073110518782914

Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway

J Law Med Ethics. 2018 Jun;46(1_suppl):43-49. doi: 10.1177/1073110518782914.

Authors

Christine Årdal¹, Jostein Johnsen¹, Karianne Johansen¹

Affiliation

¹ Christine Årdal, Ph.D., is a senior adviser on public health and antimicrobial resistance at the Norwegian Institute of Public Health. She was a co-lead on the DRIVE-AB project. Jostein Johnsen was a senior adviser on public health and pharmaceutical/vaccine supply at the Norwegian Institute of Public Health. Karianne Johansen, M.S.M., Ph.D., is a senior adviser at the Norwegian Institute of Public Health, specializing in innovation, regulatory challenges, and health technology assessment within vaccines and antibiotic resistance.

PMID: 30146956
DOI: 10.1177/1073110518782914

Abstract

No country has yet implemented a pilot to ensure access to or the innovation of new antibiotics for multi-drug infections. A team from national health agencies in Norway, with the support of the Innovative Medicine Initiative-funded project DRIVE-AB, designed a model suitable for the national context, including the selection of the antibiotics, the potential value, and the operational model.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / supply & distribution*
Drug Discovery / economics*
Drug Resistance, Microbial
Health Services Accessibility
Humans
Norway
Pilot Projects
Technology Assessment, Biomedical

Substances

Anti-Bacterial Agents